平衡评分预测新诊断老年胶质母细胞瘤患者生存
BACKGROUND: Over the past years, several treatment regimens have been recommended for elderly patients with glioblastoma (GBM), ranging from ultrahypofractionated radiotherapy (RT) over monochemotherapy (ChT) to combined radiochemotherapy (RChT).…
要点
- 年龄、MGMT启动子甲基化和KPS是独立预后因素并纳入评分。
- 评分将患者分为中位OS 2.7个月和7.8个月两组。
- 评分预后意义独立于辅助治疗方案,推荐外部验证后常规使用。
核心结论
- 该评分可区分预后差与预后较好的老年胶质母细胞瘤患者,纳入未来研究有助于提高结果可比性,常规使用前需外部验证。
主要发现
- 单因素分析中年龄、KPS、MGMT状态、切除程度、术后失语和术后运动功能障碍与OS显著相关(p<0.05)。
- 多因素分析中年龄(p 0.002)、MGMT启动子甲基化(p 0.013)和KPS(p 0.005)保持显著并纳入评分。
- 患者分为A组(中位OS 2.7个月)和B组(中位OS 7.8个月)。
- 评分预后意义独立于辅助治疗方案。
关键数值与推荐
- 当前指南推荐KPS至少60%的老年患者接受积极治疗。
- 评分基于年龄、MGMT启动子甲基化和KPS三个因素。
- 评分总和对应中位OS<6个月为A组,>6个月为B组。
临床怎么用
- 该评分可用于辅助识别老年胶质母细胞瘤中预后极差的患者,但常规使用前需外部验证。
局限性
- 回顾性研究,评分需外部验证后方可用于常规临床。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the past years, several treatment regimens have been recommended for elderly patients with glioblastoma (GBM), ranging from ultrahypofractionated radiotherapy (RT) over monochemotherapy (ChT) to combined radiochemotherapy (RChT). The current guidelines recommend active treatment in elderly patients in cases with a KPS of at least 60%. We established a score for selecting patients with a very poor prognosis from patients with a better prognosis. METHODS: One hundred eighty one patients ≥65 years old, histologically diagnosed with GBM, were retrospectively evaluated. Clinical characteristics were analysed for their impact on the overall survival (OS). Factors which were significant in univariate analysis (log-rank test, p < 0.05) were included in a multi-variate model (multi-variate Cox regression analysis, MVA). The 9-month OS for the significant factors after MVA (p < 0.05) was included in a prognostic score. Score sums with a median OS of < and > 6 months were summarized as Group A and B, respectively. RESULTS: Age, KPS, MGMT status, the extent of resection, aphasia after surgery and motor dysfunction after surgery were significantly associated with OS on univariate analysis (p < 0.05). On MVA age (p 0.002), MGMT promotor methylation (p 0.013) and Karnofsky performance status (p 0.005) remained significant and were included in the score. Patients were divided into two groups, group A (median OS of 2.7 months) and group B (median OS of 7.8 months). The score was of prognostic significance, independent of the adjuvant treatment regimen. CONCLUSIONS: The score distinguishes patients with a poor prognosis from patients with a better prognosis. Its inclusion in future retrospective or prospective trials could help enhance the comparability of results. Before its employment on a routine basis, external validation is recommended.
引用
- Straube C, Kessel KA, Antoni S, et al. A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma. Radiat Oncol. 2020. PMID: 32375830. doi:10.1186/s13014-020-01549-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。